Product image of Moxifloxacina Aurobindo (Moxifloxacin Hydrochloride) supplied by GNH India

Moxifloxacina Aurobindo

Active Ingredient:
Moxifloxacin Hydrochloride
Origin:
EU

Moxifloxacina Aurobindo (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacina Aurobindo, is a fluoroquinolone presented as an oral dosage form for systemic use. It treats a range of bacterial infections, particularly respiratory and skin infections, in adult patients as prescribed by a qualified health professional.

GNH India supplies Moxifloxacina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Generis Farmacêutica, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Moxifloxacina Aurobindo is a fluoroquinolone antibacterial used to manage several bacterial infections.

  • Community‑acquired pneumonia: eradicates the causative pathogens and improves respiratory function.
  • Acute bacterial sinusitis: reduces sinus inflammation and clears infection.
  • Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents complications.
  • Skin and soft‑tissue infections: eliminates susceptible Gram‑positive and Gram‑negative organisms.

How It Works

  • Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme‑DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death and a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Side Effects

Moxifloxacina Aurobindo may cause adverse reactions that vary in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset.
  • Diarrhea: loose stools, often self‑limiting.
  • Headache: transient cranial discomfort.
  • Dizziness: sensation of light‑headedness.
  • Abdominal pain: cramping or discomfort.
  • Rash: mild skin erythema.

Serious or Rare Side Effects

  • Tendon rupture: sudden pain or loss of function, especially in the Achilles tendon.
  • QT interval prolongation: risk of cardiac arrhythmias.
  • Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
  • Clostridioides difficile infection: severe colitis with watery diarrhea.
  • Hepatic toxicity: elevated liver enzymes or jaundice.
  • Peripheral neuropathy: numbness or tingling in extremities.

Precautions & Warnings

Before prescribing Moxifloxacina Aurobindo, clinicians should consider several safety measures.

  • Assess renal function: adjust therapy if significant impairment exists.
  • Monitor for tendon pain: discontinue if signs of tendonitis or rupture appear.
  • Avoid concomitant QT‑prolonging drugs: reduce risk of cardiac arrhythmias.
  • Use with caution in elderly patients: higher susceptibility to adverse events.
  • Discontinue on severe hypersensitivity: stop treatment if anaphylactic signs develop.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Moxifloxacina Aurobindo can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Co‑administration with other fluoroquinolones: increased toxicity risk.
  • QT‑prolonging agents (e.g., quinidine, macrolides): heightened arrhythmia potential.
  • Antacids or supplements containing magnesium/aluminum: reduce absorption.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may lower seizure threshold.
  • Corticosteroids: combined use raises tendon‑rupture risk.

Frequently Asked Questions

Moxifloxacina Aurobindo is indicated for adult patients with community‑acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and skin or soft‑tissue infections caused by susceptible bacteria. The drug targets a broad range of Gram‑positive and Gram‑negative organisms.

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By preventing the resealing of DNA strands, it leads to bacterial cell death, providing a bactericidal effect across many common pathogens.

The dosage of Moxifloxacina Aurobindo is determined by the prescribing clinician based on the specific infection, patient characteristics, and local guidelines. Patients should follow the exact regimen written on their prescription and not adjust the dose on their own.

Safety data for moxifloxacin in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Moxifloxacina Aurobindo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity in respiratory infections compared with older fluoroquinolones such as ciprofloxacin. It also has a longer half‑life, allowing once‑daily dosing, but shares class‑related safety considerations that require monitoring.

Store Moxifloxacina Aurobindo at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Moxifloxacina Aurobindo is taken orally, usually with a full glass of water. It can be taken with or without food, but antacids containing magnesium or aluminum should be spaced at least two hours apart to avoid reduced absorption.

Serious risks include tendon rupture (especially in the Achilles tendon), QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare cases of hepatic toxicity or peripheral neuropathy.

Patients with a known hypersensitivity to moxifloxacin or any fluoroquinolone should avoid the drug. It is also contraindicated in individuals with a history of tendon disorders related to fluoroquinolone use, those with significant QT prolongation, and patients taking medications that strongly interact with its metabolism without appropriate monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Moxifloxacin Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT